Molecular analysis for donor-recipient chimerism after allogeneic SCT is an important component of routine monitoring and can assist in the detection of early disease relapse. Some attempts at the standardization of the techniques, frequency of testing and types of samples for analysis have been previously suggested. 1 Although peripheral blood has been suggested to be more useful than BM in the analysis of post transplant chimerism, there have not been any studies of which we are aware of comparing peripheral blood to BM analysis. In our institution, BM samples are more commonly monitored in the pediatric population, while peripheral blood samples are more routinely examined in the adult population. We have noted that several patients have had simultaneous, or closely spaced, peripheral blood and BM sampling, some of which have shown different results with regards to chimerism. For this reason, we wanted to evaluate the sensitivity of detecting mixed chimerism in BM samples as compared to peripheral blood.
This study was approved by the institutional review board of Vanderbilt University Medical Center. The database of the molecular genetics laboratory at Vanderbilt Medical Center contains collected chimerism data on all patients transplanted at our center. Between January 2005 and June 2007, 49 patients had 63 simultaneous or closely spaced analyses of BM and peripheral blood chimerism. An extensive chart review was performed to determine age, gender, underlying diagnosis, type of transplant, conditioning therapy and outcome. All post transplant patients at our center have routine chimerism analysis at 30, 100 and 365 days post transplant. Additional chimerism analysis may be performed at the discretion of treating physician based on the patient's clinical status.
Chimerism analysis was performed by comparing high molecular weight genomic DNA extracted from whole blood specimens received from the donor and recipient prior to transplantation, and whole blood and BM on samples following transplantation. DNA (5-20 ng) from each specimen was analyzed using fluorescent PCR amplification for nine highly polymorphic independently segregating short tandem repeat (STR) loci and a gender specific locus (Applied Biosystems, Foster City, CA, USA). Two to 4 ml of the 50 ml reaction were subjected to capillary electrophoresis on an ABI 3130xl Genetic Analyzer, and the unique DNA fingerprint patterns for all specimens were characterized using the fragment analysis program GeneMapper v3.7 (Applied Biosystems).
The percent of recipient DNA chimerism in the BM and blood were compared using a Wilcoxon signed-rank test.
Because there were many tied observations at 0, the method by Bauer 2 was used to obtain the exact confidence interval for differences.
The median age of patients was 51 years (range 6-64 years); 20 were female and 29 male. Underlying diagnoses consisted of acute myelogenous leukemia (n ¼ 16), nonHodgkin's lymphoma (n ¼ 9), acute lymphoblastic leukemia (n ¼ 6), multiple myeloma (n ¼ 6), chronic myelogenous leukemia (n ¼ 6), severe aplastic anemia (n ¼ 4) and myelodysplastic syndrome (n ¼ 2). Thirty patients received a graft from a related donor and 19 from an unrelated donor, including four who had a mismatched cord blood transplant. Thirty patients received a fully ablative conditioning regimen (chemotherapy ± TBI) while 19 received a non-myeloablative conditioning regimen. All transplants were non-T-cell depleted.
Of 49 samples, 19 had 0% recipient DNA in both blood and marrow. Eight samples had less recipient DNA detected in the marrow compared to the peripheral blood, with the biggest discrepancy at 3 percentage points. Twenty-one samples had more recipient DNA detected in the marrow than in the blood. Seven of the 21 had a difference of 3 percentage points or less, while the other 14 had a difference of 4 percentage points or more. One sample had equal results for recipient DNA in blood and marrow. Overall, BM samples were more sensitive in detecting recipient DNA chimerism than peripheral blood samples (P ¼ 0.0004, 95% CI of 1.5-11.5) (Figure 1 ). Eight patients had no detectable www.nature.com/bmt recipient DNA in the peripheral blood, but the BM showed recipient chimerism ranging from 1 to 18% (Table 1) . Seven of those patients had malignant disorders and one patient had aplastic anemia. All seven of these patients experienced relapsed disease shortly after the detection of the recipient chimerism in the BM. We present the first study of simultaneous, or closely spaced peripheral blood and BM chimerism analysis in patients following allogeneic SCT. Chimerism analysis has been recognized as an important tool in documenting and following engraftment and success of SCT. Moreover, chimerism testing has been used for assessing the effectiveness of various conditioning regimens and GVHD prophylaxis. It has been shown that relapse is preceded by a transient stage of mixed chimerism. 3 Some investigators have reported that rapidly rising recipient chimerism is predictive of relapsed leukemia. 4, 5 In a recent study of 163 children with ALL who had weekly peripheral blood chimerism analysis, those with increasing mixed chimerism were at significantly higher risk of relapse. The event-free survival of those with rising mixed chimerism without immunologic intervention was 0%. 6 We have shown that measuring BM chimerism can detect significantly higher rate of mixed chimerism than doing so with peripheral blood. Of interest, seven of our patients with malignant disease who had a peripheral blood analysis showed no recipient DNA, while the marrow showed the presence of recipient DNA ranging from 1 to 18%. All of these patients experienced relapse of their primary disease. Although performing frequent BM examination might not be clinically feasible, further studies comparing BM chimerism to peripheral blood are warranted. One limitation of our study is its retrospective nature and that not all patients in our program had simultaneous peripheral blood and BM examination. We conclude that the use of BM specimens for chimerism studies may provide a more sensitive method to detect recipient chimerism and early relapse. 
